Why the study?
Does heparin-releasable PF4 differ between CAD patients and normal controls, and does low-dose aspirin reduce these levels in CAD patients?
Population
23 patients with coronary artery disease (CAD) and 15 normal control subjects.
Comparison
Intravenous injection of heparin for biomarker… vs Normal control subjects and pre-aspirin baseline…
Design
Cohort
Follow-up
246.0 ± 28.8 days (for aspirin subset)
Authors
Loading...
Heparin-releasable PF4 may mark platelet activation in CAD; hypothesis-generating for biomarker utility, should not yet change practice.
Does heparin-releasable PF4 differ between CAD patients and normal controls, and does low-dose aspirin reduce these levels in CAD patients?
Heparin-releasable PF4 is elevated in CAD patients, correlates with coronary atherosclerosis severity, and is reduced by low-dose aspirin, suggesting its utility as a marker of platelet aggregability.
Sadayasu et al. (1991) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: